US equities
|
MU
$1,040.44
▼-0.49%
NVDA
$238.52
▼-0.30%
AMD
$637.30
▼-1.87%
SNDK
$1,671.41
▲+0.66%
INTC
$113.72
▲+1.08%
SPCX
$167.55
▼-2.54%
TSLA
$375.09
▼-1.47%
MRVL
$279.85
▼-2.50%
MU
$1,040.44
▼-0.49%
NVDA
$238.52
▼-0.30%
AMD
$637.30
▼-1.87%
SNDK
$1,671.41
▲+0.66%
INTC
$113.72
▲+1.08%
SPCX
$167.55
▼-2.54%
TSLA
$375.09
▼-1.47%
MRVL
$279.85
▼-2.50%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Faeth Therapeutics, Inc. - Common Stock
(NQ:
FTH
)
26.60
-0.29 (-1.08%)
Delayed Quote
Updated: 10:13 AM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Faeth Therapeutics, Inc. - Common Stock
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
↗
Today 4:02 EDT
Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The...
Via
MarketBeat
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
September 17, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
September 08, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
September 01, 2026
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
August 17, 2026
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
August 14, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
August 07, 2026
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
August 04, 2026
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 23, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2026
From
Faeth Therapeutics, Inc.
Via
Business Wire
